GE HealthCare Technologies

GE Healthcare reported organic revenue growth of 6.2% in the third quarter to $5.5 billion and a net income increase to $615 million. The company raised its 2026 guidance: comparable revenue growth of around 4%, adjusted EBIT margin of 15.5–15.7% and adjusted earnings per share of $4.95–5.05. CEO Peter Arduini said the improvements in results and margins were broad-based across all segments. The stock jumped significantly in early trading. » Mere på finanzen.net

A $1,000 investment in GE HealthCare Technologies one year ago would now be worth only $865.27, representing a loss of 13.47%. The purchase resulted in 13.473 shares; the most recently quoted closing price was $64.22. Market capitalization was last reported at $29.13 billion. Stock splits and dividends are not taken into account in the calculation. » Mere på finanzen.net

Had $1,000 been invested in GE HealthCare Technologies three years ago (share price then $66.28), it would have bought 15.088 shares. At the closing price of $64.45 on September 17, 2026, those would have been worth $972.31, a decline of 2.77%. The company's market value was most recently $28.62 billion; stock splits and dividends were not taken into account in the calculation. » Mere på finanzen.net

A $100 investment in GE HealthCare Technologies one year ago would be worth about $82.40 today, a decline of roughly 17.6%. The stock's closing price on September 10, 2026, was $64.24. Market capitalization is reported at approximately $29.44 billion. » Mere på finanzen.net

GE HealthCare reports order growth of 11%, a book-to-bill of 1.15 and an order backlog of USD 2.1bn, driven mainly by service contracts. Management expects an acceleration in organic growth and a sequential margin improvement of around 250 basis points in the second half of the year, despite headwinds from tariffs, supply-chain issues and storage costs (~200 basis points). The patient care solutions division is expected to recover operationally but is under strategic review, while pharmaceutical diagnostics and new imaging products such as Photonova Spectra will support margin-rich growth. China is stabilizing after declines, but a slight decline for 2024 is still expected. » Mere på de.investing.com